Slit Guidance Ligand 2 (SLIT2) binds Roundabout (ROBO) guidance receptors to direct axon pathfinding and neuron migration during nervous system development. SLIT2 expression has previously been linked to dementia risk.
Objective
To study the association between SLIT2 expression in human vitreous humor and plasma samples and neurocognitive test scores in a cross-sectional cohort study utilizing a novel, highly-sensitive Meso Scale Discovery (MSD) assay for SLIT2 detection.
Methods
Seventy-nine individuals with a mean age of 55.79 ± 12.03 years underwent eye surgery with collection of vitreous humor, blood (plasma) collection, and neurocognitive assessment. Vitreous humor and plasma samples were analyzed by SLIT2 MSD electrochemiluminescence immunoassay. Associations between SLIT2 levels in vitreous humor and plasma were analyzed using GraphPad Prism.
Results
We found up to a 7-fold higher level of SLIT2 in human vitreous humor compared to plasma. Lower vitreous SLIT2 levels were associated with a lower Montreal Cognitive Assessment (MoCA) score and Immediate Recall Verbatim (IRV) z-score, and higher plasma SLIT2 was associated with a lower MoCA score. In multivariate analysis using single and multiple predictor models, the same significant associations were found when adjusted for age, sex, race, diabetic status, diabetic retinopathy status, glaucoma status, and Apolipoprotein E (APOE) genotype.
Conclusions
SLIT2 protein levels are significantly associated with MoCA score and IRV z-score in middle-aged individuals. The relationship remained significant when adjusted for demographics, co-morbidity, and APOE genotype, suggesting SLIT2 may be a sensitive biomarker for detection of mild cognitive impairment and early dementia, and warrants further studies.
KovacsGG. Molecular pathology of neurodegenerative diseases: principles and practice. J Clin Pathol2019; 72: 725–735.
2.
RekatsinaMPaladiniAPiroliA, et al.Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: a narrative review. Adv Ther2020; 37: 113–139.
3.
DuggerBNDicksonDW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol2017; 9: a028035.
4.
WebberCJLeiSWolozinB. The pathophysiology of neurodegenerative disease: disturbing the balance between phase separation and irreversible aggregation. Prog Mol Biol Transl Sci2020; 174: 187–223.
5.
ZaibSJavedHKhanI, et al.Neurodegenerative diseases: their onset, epidemiology, causes and treatment. ChemistrySelect2023; 8: e202300225.
6.
ReljaM. Pathophysiology and classification of neurodegenerative diseases. EJIFCC2004; 15: 97–99.
7.
Pérez PalmerNTrejo OrtegaBJoshiP. Cognitive impairment in older adults: epidemiology, diagnosis, and treatment. Psychiatr Clin North Am2022; 45: 639–661.
8.
AkushevichIYashkinAPKravchenkoJ, et al.Time trends in the prevalence of neurocognitive disorders and cognitive impairment in the United States: the effects of disease severity and improved ascertainment. J Alzheimers Dis2018; 64: 137–148.
9.
ErkkinenMGKimMOGeschwindMD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol2018; 10: a033118.
LoiSMCationsMVelakoulisD. Young-onset dementia diagnosis, management and care: a narrative review. Med J Aust2023; 218: 182–189.
13.
LogroscinoGUrsoDSavicaR. Descriptive epidemiology of neurodegenerative diseases: what are the critical questions?Neuroepidemiology2022; 56: 309–318.
14.
OlssonBPorteliusECullenNC, et al.Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol2019; 76: 318–325.
15.
LinYSLeeWJWangSJ, et al.Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep2018; 8: 17368.
16.
KimKYShinKYChangKA. Brain-derived exosomal proteins as effective biomarkers for Alzheimer's disease: a systematic review and meta-analysis. Biomolecules2021; 11: 980.
17.
AskenaziMKavanaghTPiresG, et al.Compilation of reported protein changes in the brain in Alzheimer's disease. Nat Commun2023; 14: 4466.
18.
SampaniKNessSTuz-ZahraF, et al.Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study. Alzheimers Res Ther2024; 16: 192.
19.
WrightLMSteinTDJunG, et al.Association of cognitive function with amyloid-β and tau proteins in the vitreous humor. J Alzheimers Dis2019; 68: 1429–1438.
20.
VigVGargITuz-ZahraF, et al.Vitreous humor biomarkers reflect pathological changes in the brain for Alzheimer’s disease and chronic traumatic encephalopathy. J Alzheimers Dis2023; 93: 1181–1193.
21.
SubramanianMLVigVChungJ, et al.Neurofilament light chain in the vitreous humor of the eye. Alzheimers Res Ther2020; 12: 111.
22.
FereshetianSAgranatJSSiegelN, et al.Protein and imaging biomarkers in the eye for early detection of Alzheimer’s disease. J Alzheimers Dis Rep2021; 5: 375–387.
23.
RamaNDubracAMathivetT, et al.Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization. Nat Med2015; 21: 483–491.
24.
TongMJunTNieY, et al.The role of the SLIT/Robo signaling pathway. J Cancer2019; 10: 2694–2705.
SasakiTKomatsuYYamamoriT. Expression patterns of SLIT/ROBO mRNAs reveal a characteristic feature in the entorhinal-hippocampal area of macaque monkeys. BMC Res Notes2020; 13: 262.
27.
XuCFanCM. Expression of Robo/Slit and Semaphorin/Plexin/Neuropilin family members in the developing hypothalamic paraventricular and supraoptic nuclei. Gene Expr Patterns2008; 8: 502–507.
28.
PlachezCAndrewsWLiapiA, et al.Robos are required for the correct targeting of retinal ganglion cell axons in the visual pathway of the brain. Mol Cell Neurosci2008; 37: 719–730.
29.
ThompsonHAndrewsWParnavelasJG, et al.Robo2 is required for Slit-mediated intraretinal axon guidance. Dev Biol2009; 335: 418–426.
30.
DavisonCZolessiFR. Slit2 is necessary for optic axon organization in the zebrafish ventral midline. Cells Dev2021; 166: 203677.
31.
DicksonBJ. Molecular mechanisms of axon guidance. Science2002; 298: 1959–1964.
32.
SherchanPTravisZDTangJ, et al.The potential of Slit2 as a therapeutic target for central nervous system disorders. Expert Opin Ther Targets2020; 24: 805–818.
33.
ZhangLQiZLiJ, et al.Roles and mechanisms of axon-guidance molecules in Alzheimer’s disease. Mol Neurobiol2021; 58: 3290–3307.
34.
BaiBWangXLiY, et al.Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron2020; 105: 975–991.e7.
35.
WangHDeyKKChenPC, et al.Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Mol Neurodegener2020; 15: 43.
36.
KivimäkiMWalkerKAPenttiJ, et al.Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: three analyses of population cohort studies. Br Med J2021; 374: n1804.
37.
BaiGChivatakarnOBonanomiD, et al.Presenilin-dependent receptor processing is required for axon guidance. Cell2011; 144: 106–118.
38.
ZhouWWangHYuW, et al.The expression of the Slit-Robo signal in the retina of diabetic rats and the vitreous or fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. PLoS One2017; 12: e0185795.
39.
DanielBAgenagnewLWorkichoA, et al.Psychometric properties of the Montreal Cognitive Assessment (MoCA) to detect major neurocognitive disorder among older people in Ethiopia: a validation study. Neuropsychiatr Dis Treat2022; 18: 1789–1798.
40.
SchroederRWMartinPKWallingA. Neuropsychological evaluations in adults. Am Fam Physician2019; 99: 101–108.
41.
WeintraubSBesserLDodgeHH, et al.Version 3 of the Alzheimer disease Centers’ neuropsychological test battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord2018; 32: 10–17.
42.
Neuropsychological Battery Tests reported on Form C2, Uniform Data Set (UDS) v3.0, www.alz.washington.edu (2006).
43.
ReimanEMArboleda-VelasquezJFQuirozYT, et al.Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun2020; 11: 667.
44.
CorderEHSaundersAMStrittmatterWJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993; 261: 921–923.
45.
CorderEHSaundersAMRischN, et al.Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet1994; 7: 180–184.
46.
BatemanRJXiongCBenzingerTLS, et al.Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med2012; 367: 795–804.
47.
MehtaPDPirttiläTMehtaSP, et al.Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol2000; 57: 100–105.
48.
BlennowKZetterbergH. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med2018; 284: 643–663.
49.
OlssonBLautnerRAndreassonU, et al.CSF And blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol2016; 15: 673–684.
50.
CipolliniVTroiliFGiubileiF. Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application. Int J Mol Sci2019; 20: 2812.
51.
FakhouryM. Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener Dis2015; 15: 63–69.
52.
FernandoRGrisoliaABDLuY, et al.Slit2 modulates the inflammatory phenotype of orbit-infiltrating fibrocytes in Graves’ disease. J Immunol2018; 200: 3942–3949.
53.
LiQHuangLDingY, et al.Recombinant Slit2 suppresses neuroinflammation and Cdc42-mediated brain infiltration of peripheral immune cells via Robo1-srGAP1 pathway in a rat model of germinal matrix hemorrhage. J Neuroinflammation2023; 20: 249.
54.
LiJCHanLWenYX, et al.Increased permeability of the blood-brain barrier and Alzheimer’s disease-like alterations in slit-2 transgenic Mice. J Alzheimers Dis2015; 43: 535–548.
55.
LiGHeXLiH, et al.Overexpression of Slit2 improves function of the paravascular pathway in the aging mouse brain. Int J Mol Med2018; 42: 1935–1944.
56.
KanekoNHerranz-PérezVOtsukaT, et al.New neurons use slit-robo signaling to migrate through the glial meshwork and approach a lesion for functional regeneration. Sci Adv2018; 4: eaav0618.
57.
ZhangJChenCHuaS, et al.An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clin Pract2017; 124: 41–47.
58.
KangYEChoungSLeeJH, et al.The role of circulating slit2, the one of the newly batokines, in human diabetes mellitus. Endocrinol Metab (Seoul)2017; 32: 383–388.
59.
WangYZhaoSPengW, et al.The role of slit-2 in gestational diabetes mellitus and its effect on pregnancy outcome. Front Endocrinol (Lausanne)2022; 13: 889505.
60.
JashKGondaliyaPKiraveP, et al.Cognitive dysfunction: a growing link between diabetes and Alzheimer’s disease. Drug Dev Res2020; 81: 144–164.
61.
LiRLiRXieJ, et al.Associations of socioeconomic status and healthy lifestyle with incident early-onset and late-onset dementia: a prospective cohort study. Lancet Healthy Longev2023; 4: e693–e702.
62.
BosiMMalavoltiMGarutiC, et al.Environmental and lifestyle risk factors for early-onset dementia: a systematic review. Acta Biomed2022; 93: e2022336.
63.
OuyangFYuanPJuY, et al.Alzheimer's disease as a causal risk factor for diabetic retinopathy: a Mendelian randomization study. Front Endocrinol (Lausanne)2024; 15: 1340608.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
